novo nordisk glp 1 drugs Novo, Lilly weight-loss should be first option obesity treatments, European doctors say Novo Nordisk launches its Wegovy

Several observational studies have examined the potential association between GLP-1RAs and suicidality, with mixed findings regarding suicidal ideation, self-harm, and suicide risk [49]

is a consultant to Pfizer and Novo Nordisk

Activated microglia in patients with AD release proinflammatory factors, which further promote ROS production, creating a vicious cycle of neuroinflammation and mitochondrial dysfunction (Qian et al., 2025)

Both represent the minimum therapeutic dose designed to introduce your body to the medication with minimal side effects

Example in development - Triple agonists targeting GLP-1, GIP, and glucagon are in early trials

Demonstrating efficacy in obesity-related comorbidities will be paramount in order to achieve reimbursement in Europe, yet it will take time for trials focused on these co-morbidities to translate into label expansion and revenues